書誌事項
- タイトル別名
-
- B Cells as Key Contributors in Determining the Level of Immune Responses : B-Cell-Targeted Therapy in Patients with Autoimmune Diseases
- B サイボウ ニ ヨル メンエキ オウトウ チョウセツ ト ソノ リンショウテキ イギ B サイボウ オ ヒョウテキ ト シタ ジコ メンエキ シッカン ノ チリョウ
この論文をさがす
抄録
The levels and types of immune responses are determined dependent on the extent of pathogen invasion, reactions to antigens mediated by macrophage-dendritic cells, T cells and antibodies. Recently, accumulating evidence suggests that B cells also play an important role in the regulation of immune responses. Here we have made a review to present a role of B cells in determining the level of immune responses and discussed about the clinical significance of B cell-targeted therapy in patients with autoimmune diseases. Type 1 diabetes is a T cell-mediated autoimmune disease characterized by the destruction of insulin-producing pancreatic A3 cells. We and other groups have elucidated that B cells play a critical role in the development of insulitis and diabetes, as B-cell-deficient NOD mice are protected from developing type 1 diabetes. B cells are essential for the T cell receptor clonotype spreading of islet-infiltrating T cells, indicating that B cells may play a role in determining the level of immune responses by antigen presentation to antigen specific T cells. There are now numerous case reports and small series of clinical trials regarding rituximab therapy in autoimmune diseases, such as refractory autoimmune hemolytic anemia, IgM antibody-associated polyneuropathy, systemic lupus erythematosus and rheumatoid arthritis. Rituximab is a genetically engineered chimeric anti-CD 20 monoclonal antibody that is approved for the treatment of lymphoma. CD20 is a B-cell surface antigen that is expressed only on pre B and mature B cells. Thus, rituximab causes a selective transient depletion of the CD20+ B -cell subpopulation . Rationale and strategy for targeting B cells in the treatment of autoimmune diseases consist of the inhibition of antigen-presentation and co-stimulation that induces T cell expansion and activation. Further careful mechanistic studies are required to develop therapies in patients with autoimmune diseases.
収録刊行物
-
- 福岡醫學雜誌
-
福岡醫學雜誌 96 (4), 86-92, 2005-04-25
福岡医学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390290699740411520
-
- NII論文ID
- 120002834545
-
- NII書誌ID
- AN00215478
-
- DOI
- 10.15017/19265
-
- HANDLE
- 2324/19265
-
- NDL書誌ID
- 7418332
-
- ISSN
- 0016254X
-
- PubMed
- 15991605
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- IRDB
- NDL
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用可